argenx SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARGX research report →
Range $861 – $1400
Price Chart
About the company
argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation.
- CEO
- Karen Massey
- IPO
- 2017
- Employees
- 1,863
- HQ
- Amsterdam, NH, NL
AI snapshot
Six angles, distilled from the data.
The stock remains in a strong multi-month uptrend and sits well above its 200-day average of 860.28, with the 50-day at 923.88 also trending higher. It is trading in the upper half of its 52-week range, below the 1,072.75 high but far above the 661.85 low, which keeps the secular setup constructive.
Street sentiment stays firmly positive: the consensus rating is Buy, with 31 Buy, 4 Hold, and 0 Sell calls. The target cluster has been trimmed in places, but the consensus target of 1,152.06 still sits above the current share price, and recent changes show mostly reiterated bullish views rather than downgrades.
The earnings pattern is strong, with 7 beats in the last 8 quarters and the latest quarter topping estimates by 4.8%. Next-year EPS estimates point to 33.31 from 28.87 TTM, so shareholders should watch whether VYVGART demand and pipeline execution can keep the beat streak intact.
No notable insider buying or selling in recent quarters. With no reported transactions, there is no discretionary insider signal to read into.
Profitability is solid, with a 59.8% gross margin, 31.94% operating margin, and 31.73% net margin. Growth remains strong too, with revenue up 52.1% year over year and earnings up 50.6%, while the balance sheet shows 4.44 billion in cash against just 83.49 million of debt.
argenx stands out as a premium biotech with commercial-stage autoimmune exposure and a cleaner balance sheet than many peers. The market is valuing that quality at 34.62 times earnings, a rich multiple that leaves less room for execution slips.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $58.21B
- P/E
- 44.27
- Fwd P/E
- 33.72
- PEG
- 2.31
- P/S
- 13.23
- P/B
- 7.02
- EV/EBITDA
- 40.21
- Div Yield
- 0.00%
- Gross Margin
- 90.49%
- Op Margin
- 29.35%
- Net Margin
- 29.64%
- ROE
- 16.86%
- ROIC
- 13.96%
Latest fiscal year · YoY change
- Revenue
- $4.15B+89.6%
- Gross Profit
- $3.70B+88.6%
- Op Income
- $1.05B
- Net Income
- $1.29B+55.1%
- EPS
- $21.14+51.9%
- OCF Growth
- +928.1%
- FCF Growth
- +549.5%
- 52W High
- $1072.75
- 52W Low
- $661.85
- 50D MA
- $918.99
- 200D MA
- $862.29
- Beta
- -0.02
- RSI (14)
- 54
- Avg Volume
- 361.64K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Argenx posted another strong quarter with 54% year-over-year product sales growth, expanding margins, and a growing late-stage pipeline that management says keeps it on track for Vision 2030.· October 22, 2026
- Product net sales were $1.7 billion, up 54% year-over-year and 13% quarter-over-quarter; operating profit was $486 million with a 28% margin.
- VYVGART growth remains broad-based across MG and CIDP, helped by the seronegative MG launch, which already covers about 96% of covered lives.
- Management highlighted multiple near-term catalysts: pediatric MG (PDUFA early 2027), ocular MG filing, IMNM sBLA by year-end, and the VYVGART Hytrulo auto-injector in 2H 2027.
- The empasiprubart MMN readout is expected in December, and management said a positive result could support a 2027 launch and priority review.
- FB102 showed positive Phase II celiac data, and argenx expects 10 molecules in clinical development by year-end.
Product net sales were $1.7 billion, up 54% year-over-year and 13% quarter-over-quarter. U.S. product net sales were $1.5 billion; Japan $81 million; Rest of World $158 million; and product supplied to Zai Lab in China $11 million. Gross to net deductions were 22%. Total operating expenses were $1.3 billion; combined R&D and SG&A were $1.1 billion, up 22% quarter-over-quarter, including $150 million of Forte acquisition-related costs. Operating profit was $486 million, with a 28% operating margin; adjusted for Forte transaction-related costs, operating margin was 37%. The year-to-date effective tax rate was 10%. The company ended the quarter with $3.7 billion in cash, cash equivalents and current financial assets after paying a net $2.1 billion for the Forte acquisition. For full-year 2026, management now expects combined R&D and SG&A expenses of approximately $4 billion. Management did not provide revenue guidance, but said revenue growth continues to outpace expense growth and that it expects to continue investing with discipline.
Karen Massey described the quarter as another “outstanding” one and emphasized that argenx is still early in realizing VYVGART’s potential across MG and CIDP nearly five years after launch. Her tone was confident and expansive, centering on Vision 2030 and a pipeline strategy built around novel biology, multiple indications, and repeated launches. She repeatedly framed 2027 as a major inflection year, with up to five U.S. launches possible and several programs moving toward late-stage or filing milestones. She also stressed disciplined risk-taking, noting the company moves early, fast, and will stop early when needed.
Karl Gubitz highlighted strong operating leverage and said revenue growth is continuing to outpace expense growth. He reported $1.7 billion in product sales, $1.3 billion in total operating expenses, $1.1 billion in combined R&D and SG&A, and $486 million in operating profit, with margin at 28% or 37% excluding the Forte transaction-related costs. He said $150 million of Forte acquisition cost was included in the quarter and that full-year 2026 combined R&D and SG&A is now expected to be about $4 billion, driven by Forte, FB102 investment, commercial buildout after ALKIVIA, and progress across 10 assets in the clinic. He closed by reiterating capital allocation priorities: strengthen VYVGART, advance a diversified pipeline, and preserve financial flexibility.
Analysts focused on ALKIVIA follow-up, the design of a future dermatomyositis trial, MMN’s non-inferiority framework, OpEx guidance, and whether Vision 2030 still looks achievable after recent program setbacks. Management said the DM filing discussion with FDA clarified the path and that the team is now designing what it believes is the most efficient Phase III approach, but did not disclose the exact design. On MMN, management said the non-inferiority margin is not public, but the head-to-head design versus IVIg was chosen based on ARDA learnings and the expectation that empasiprubart can match IVIg while reducing burden; superiority would be upside. On Vision 2030, Karen said the company remains “well on track,” with MG and CIDP expected to provide the bulk of patient growth and multiple additional launches contributing, while Karl said the company may give more expense clarity at JPMorgan but not formal revenue guidance yet.
The quarter showed strong commercial momentum, with 54% year-over-year sales growth and broad adoption across MG and CIDP. Management pointed to multiple late-stage and filing catalysts, including pediatric MG, ocular MG, IMNM, MMN, and FB102, which could deepen growth beyond the current franchise. They also emphasized operating leverage, strong cash generation, and a pipeline that they believe can support Vision 2030 and beyond.
The company still faces binary clinical and regulatory risk, especially for DM, MMN, and the broader rheumatology pipeline, and management acknowledged that some programs will require new trials or additional agency alignment. OpEx is rising materially to about $4 billion for 2026, and management said not to assume another 45% increase in 2027, which signals ongoing heavy investment. They also noted that launch uptake in IMNM may take about two quarters after approval to secure payer coverage, and that some recent programs have failed or been stopped, reminding investors that not every bet will work.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 62.89M
- Float Shares
- 62.76M
of shares held by institutions
530 13F filers
Congressional trading
Senate and House stock disclosures for ARGX, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 5.36M | ▲ 126.08K |
| Price T Rowe Associates Inc | 2.68M | ▼ 696.91K |
| Janus Henderson Group Ltd. | 2.54M | ▲ 83.57K |
| Jupiter Topco LLC | 2.47M | ▲ 2.47M |
| Capital World Investors | 2.28M | ▲ 79.43K |
| Artisan Partners Limited Partnership | 1.17M | ▼ 343.03K |
| Avoro Capital Advisors LLC | 1.00M | 0 |
| Wellington Management Group Llp | 930.55K | ▼ 90.91K |
| Blackrock, Inc. | 879.25K | ▲ 102.02K |
| Rtw Investments, LP | 709.45K | 0 |
| Morgan Stanley | 586.53K | ▼ 56.60K |
| Invesco Ltd. | 419.04K | ▼ 24.95K |
Held by 283 ETFs
Biggest fund positions in ARGX by dollar value.
Our ARGX coverage
Recent articles, reports, and earnings notes.

argenx NV ADR (ARGX): VYVGART Growth Drives a Buy Case
argenx is scaling rapidly on VYVGART strength, with Q2 2026 product sales up 60% year over year and a deep autoimmune pipeline supporting the next leg of growth. The stock remains a Buy, though valuation is already reflecting much of the execution.

argenx SE (ARGX) falls 14% after UNITY trial halt
argenx SE (ARGX) falls sharply after the company stopped its Phase 3 UNITY trial in Sjögren's disease for futility. The selloff outweighs positive FB102 celiac data, as investors reassess pipeline expansion prospects and the stock's valuation after a major late-stage setback.

Should You Buy the TRex Bio IPO? Here's the Setup
TRex Bio Inc. (NASDAQ: TRXB) is expected to list on 2026-10-09, with the IPO priced at $14.00 per share on the NASDAQ. The company offered 8,333,334 shares and disclosed a market cap of $113,287,167 in the calendar data. The bull case is a differentiated immunology platform; the bear case is a clinical-stage biotech with no product revenue and heavy execution risk.
Want a deeper read on ARGX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
zacks.com · Nov 20
Aberdeen Group plc Sells 1,479 Shares of argenex SE $ARGX
defenseworld.net · Nov 15
NVIDIA (NASDAQ:NVDA) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.
defenseworld.net · Nov 13
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
prnewswire.com · Nov 12
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
globenewswire.com · Nov 10
3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
fool.com · Nov 9
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
globenewswire.com · Nov 9
argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
globenewswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 15, 2026 · Live quote · Not investment advice